| abstract |
FIELD: medicine.SUBSTANCE: group of inventions relates to oncology, and can be used in the treatment of myelofibrosis. According to the invention, the methods comprise administering to a patient a therapeutically effective amount of a serum amyloid P (SAP) agonist, glycosylated human SAP polypeptide comprising an N-linked oligosaccharide chain, wherein the at least one branch of the oligosaccharide chain terminating with a α2,3-linked sialic acid, one or multiple times at initial loading dose during the first week of administration, and then once every 1–4 weeks.EFFECT: use of inventions allows restoring bone marrow function by decreasing fibrosis in patients.32 cl, 4 dwg, 4 tbl, 6 ex |